Publication Name	World Journal of Hepatology
Manuscript ID	32603
Country	Singapore

Received	2017-01-17 10:07
Peer-Review Started	2017-01-18 13:54
To Make the First Decision	2017-05-08 09:23
Return for Revision	2017-05-09 16:29
Revised	2017-05-20 00:55
Second Decision	2017-06-02 00:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-06-13 05:03
Articles in Press	2017-06-13 05:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-08-14 08:00
Publish the Manuscript Online	2017-08-18 01:45

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Use of everolimus in liver transplantation
Manuscript Source	Invited Manuscript
All Author List	Mei-Ling Yee and Hui-Hui Tan
Funding Agency and Grant Number
Corresponding Author	Mei-Ling Yee, Senior Principal Clinical Pharmacist, Department of Pharmacy, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. yee.mei.ling@sgh.com.sg
Key Words	Everolimus; Mammalian target of rapamycin inhibitor; Immunosuppression; Liver transplantation; Nephrotoxicity
Core Tip	Everolimus is the most recently approved im­munosuppressant for use in liver transplantation (LT). Its renoprotective effect is an attractive option for LT recipients who have calcineurin inhibitor-induced nephrotoxicity. This review examines through data published, discovers gaps of evidences and discusses the place in therapy for everolimus (EVR) in LT. At the end of review, it summarises how EVR can benefit LT recipients as well as the caveat in using EVR.
Publish Date	2017-08-18 01:45
Citation	Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol 2017; 9(23): 990-1000
URL	http://www.wjgnet.com/1948-5182/full/v9/i23/990.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i23.990

Full Article (PDF)	WJH-9-990.pdf
Full Article (Word)	WJH-9-990.doc
Manuscript File	32603-Review.docx
Answering Reviewers	32603-Answering reviewers.pdf
Audio Core Tip	32603-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	32603-Conflict-of-interest statement.pdf
Copyright License Agreement	32603-Copyright assignment.pdf
Peer-review Report	32603-Peer-review(s).pdf
Scientific Misconduct Check	32603-Scientific misconduct check.pdf
Scientific Editor Work List	32603-Scientific editor work list.pdf